Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,489 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | May 20, 2020 | clinicaltrials |
| NCT04368182 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | terminated | Phase 1 / Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT03971747 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 9 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02240433 | A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03203005 | IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute, NaplesOTHER | 5 | Feb 5, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma(NUANCE) | terminated | Phase 1 | 1 | University of UtahOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | withdrawn | Phase 1 | 0 | University of HawaiiOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Sep 25, 2019 | clinicaltrials |
| NCT02814461 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | completed | Phase 1 | 9 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT03008343 | Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02395250 | Anti-GPC3 CAR T for Treating Patients With Advanced HCC | completed | Phase 1 | 13 | RenJi HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03993743 | A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 34 | Xijing HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04032392 | Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells | unknown | Phase 1 | 20 | Beijing 302 HospitalOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | terminated | Phase 1 | 3 | Aeon Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT01008917 | Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 25 | University of California, San FranciscoOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT03899415 | TCR-Redirected T Cells Therapy in Patient With HBV Related HCC | unknown | Phase 1 | 10 | Beijing 302 HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03908840 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 12 | Evolve BiologicsINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02151864 | LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis | completed | Phase 1 | 9 | Jason K. Sicklick, M.D.OTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00441376 | A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver | completed | Phase 1 | 30 | ImunonINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT00946153 | Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 66 | Eisai Co., Ltd.INDUSTRY | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT01306058 | Sorafenib and TRC105 in Hepatocellular Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT03793322 | The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma | unknown | Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT02069041 | A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer | completed | Phase 1 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT02719782 | A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation | unknown | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2020source: clinicaltrials